162 related articles for article (PubMed ID: 37864307)
1. Spatial relationship of tertiary lymphoid structures and tumor-associated neutrophils in bladder cancer and prognostic potential for anti-PD-L1 immunotherapy.
Wang X; Juncker-Jensen A; Huang G; Nagy ML; Lu X; Cheng L; Lu X
Cancer Commun (Lond); 2024 Apr; 44(4):499-503. PubMed ID: 37864307
[No Abstract] [Full Text] [Related]
2. CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.
Rouanne M; Arpaia N; Marabelle A
Eur J Cancer; 2021 Jul; 151():245-248. PubMed ID: 33972155
[No Abstract] [Full Text] [Related]
3. Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.
Zhou L; Xu B; Liu Y; Wang Z
Oncoimmunology; 2021 May; 10(1):1915574. PubMed ID: 34104539
[TBL] [Abstract][Full Text] [Related]
4. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
[TBL] [Abstract][Full Text] [Related]
5. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
6. Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer.
Zhang Y; Li J; Yang F; Zhang X; Ren X; Wei F
J Leukoc Biol; 2022 Dec; 112(6):1591-1603. PubMed ID: 35501298
[TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
8. Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
Shen C; Zhang DL; Cheng XL; Zhang WC; Zhao JJ
Urol Int; 2023; 107(9):841-847. PubMed ID: 37769625
[TBL] [Abstract][Full Text] [Related]
9. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
10. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
Li X; Wan Z; Liu X; Ou K; Yang L
Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511
[TBL] [Abstract][Full Text] [Related]
11. Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy.
Xu W; Yang J; Ye S; Liu W; Lu J; Anwaier A; Zhang H; Ye D
Immunotherapy; 2024 Feb; 16(3):131-134. PubMed ID: 38112020
[No Abstract] [Full Text] [Related]
12. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
13. [Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer].
Liu Y; Xiong L; Cai R; Chen Y; Ye J; Shen B; Zhou G
Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):615-620. PubMed ID: 37752541
[TBL] [Abstract][Full Text] [Related]
14. Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma.
Zhang T; Lei X; Jia W; Li J; Nie Y; Mao Z; Wang Y; Tao K; Song W
Cancer Med; 2023 Feb; 12(3):3068-3078. PubMed ID: 36082777
[TBL] [Abstract][Full Text] [Related]
15. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
Front Immunol; 2022; 13():794217. PubMed ID: 35173719
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of PD-L1 in bladder cancer.
Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
[TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
N J; J T; Sl N; Gt B
Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820
[TBL] [Abstract][Full Text] [Related]
19. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures.
Li R; Berglund A; Zemp L; Dhillon J; Putney R; Kim Y; Jain RK; Grass GD; Conejo-Garcia J; Mulé JJ
Front Immunol; 2021; 12():694079. PubMed ID: 34267760
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
